Collaborations

• SFB 1309 - Chemical Biology of Epigenetic Modifications, research on the development of novel sirtuin inhibitors
• Prof. Dr. Dr. Christian Grimm, Walther Straub Institute for Pharmacology and Toxicology, LMU Munich, Prof. Dr. Martin Biel, Department of Pharmacy, Molecular Pharmacology, LMU Munich (development of novel cation channel modulators)
• Prof. Dr. Sandip Patel, University College London (UCL), Division of Biosciences, London (UK) (development of novel cation channel modulators)
• Prof. Dr. Manfred Jung, Pharmazeutisches Institut, Universität Freiburg (inhibitors of sirtuins and und histone deacetylases)
• Prof. Dr. Simone Moser, University of Innsbruck (yeast three-hybrid screening for identification of targets of bioactive natural products)
• Prof. Dr. Martin Giera, Metabolomics Group, Leiden University Medical Center (LUMC), Leiden (NL) (lipidomics for development of novel antiinflammatory drugs)
• Dr. Ulrike Binder, Prof. Dr. Cornelia Lass-Flörl, Section for Hygiene and Medicinal Microbiology (HMM), Medical University of Innsbruck, Austria (metabolism of pathogenic fungi and susceptibility to antifungal therapy)
• Prof. Dr. Erika von Mutius, Helmholtz Zentrum München (development of antiasthmatic drugs)
• Prof. Dr. Judith Rollinger, Division of Pharmacognosy, University of Vienna (protein kinase inhibitors)
• Prof. Dr. Verena Dirsch, Division of Pharmacognosy, University of Vienna (protein kinase inhibitors)
• Prof. Dr. Benedikt Sabaß, Experimentelle Physik/Medizinphysik, TU Dortmund (blockers of ruminal methane production)
• Prof. Dr. Chinnaswamy Jagannath, Weill Cornell Medical School, Houston, USA (development of drugs against tuberculosis and HIV).